Skip to content
Open access · CC-BY via OpenAlex

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer

Joshua T. Burgess, Maddison Rose, Didier Boucher, Jennifer Plowman, Christopher Molloy, Mark A. Fisher, Connor Gerard O’Leary, Derek J. Richard, Kenneth John O'Byrne, Emma Bolderson

Frontiers in Oncology · 2020 · ▲ 55 citations

Abstract

Despite advances in our understanding of the molecular biology of the disease and improved therapeutics, lung cancer remains the most common cause of cancer-related deaths worldwide. Therefore, an unmet need remains for improved treatments, especially in advanced stage disease. Genomic instability is a universal hallmark of all cancers. Many of the most commonly prescribed chemotherapeutics, including platinum-based compounds such as cisplatin, target the characteristic genomic instability of tumors by directly damaging the DNA. Chemotherapies are designed to selectively target rapidly dividing cells, where they cause critical DNA damage and subsequent cell death (1, 2). Despite the initial efficacy of these drugs, the development of chemotherapy resistant tumors remains the primary concern for treatment of all lung cancer patients. The correct functioning of the DNA damage repair machinery is essential to ensure the maintenance of normal cycling cells. Dysregulation of these pathways promotes the accumulation of mutations which increase the potential of malignancy. Following the development of the initial malignancy, the continued disruption of the DNA repair machinery may result in the further progression of metastatic disease. Lung cancer is recognized as one of the most genomically unstable cancers (3). In this review, we present an overview of the DNA damage repair pathways and their contributions to lung cancer disease occurrence and progression. We conclude with an overview of current targeted lung cancer treatments and their evolution toward combination therapies, including chemotherapy with immunotherapies and antibody-drug conjugates and the mechanisms by which they target DNA damage repair pathways.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3389/fonc.2020.01256
Canonical
link ↗
Fetched
2026-10-04 MST

Cite this

APA
Burgess, J.T., Rose, M., Boucher, D., Plowman, J., Molloy, C., Fisher, M.A., O’Leary, C.G., Richard, D.J., O'Byrne, K.J., &amp; Bolderson, E. (2020). The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. <em>Frontiers in Oncology</em>. https://doi.org/10.3389/fonc.2020.01256
Vancouver
Burgess JT, Rose M, Boucher D, Plowman J, Molloy C, Fisher MA, et al. The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. Frontiers in Oncology. 2020. doi:10.3389/fonc.2020.01256.
BibTeX
@article{joshua2020TheThe, title = {The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer}, author = {Joshua T. Burgess and Maddison Rose and Didier Boucher and Jennifer Plowman and Christopher Molloy and Mark A. Fisher and Connor Gerard O’Leary and Derek J. Richard and Kenneth John O'Byrne and Emma Bolderson}, journal = {Frontiers in Oncology}, year = {2020}, doi = {10.3389/fonc.2020.01256}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings